From: High-dose thiotepa-related neurotoxicity and the role of tramadol in children
Patients (N = 251) | |
---|---|
Gender | |
Boys | 145 (58%) |
Girls | 106 (43%) |
Age (years; median [IQR]) | 8 [5–15] |
Race | |
Caucasian | 186 (74%) |
African | 40 (16%) |
Others | 25 (10%) |
Brain tumour | 116 (46%) |
Medulloblastoma | 71 (28%) |
PNETa | 26 (10%) |
Pinealoblastoma | 13 (5%) |
ATRTb | 5 (2%) |
Malignant GCTc | 1 (0.4%) |
Other tumour site | 135 (54%) |
Osteosarcoma | 50 (20%) |
Neuroblastoma | 26 (10%) |
Ewing tumor | 23 (9%) |
Rhabdomyosarcoma | 20 (8%) |
Other sarcoma | 4 (2%) |
Nephroblastoma | 4 (2%) |
Burkitt lymphoma | 4 (2%) |
Hepatoblastoma | 2 (1%) |
Desmoplastic tumour | 2 (1%) |
Neurological disorder at baselined | 20 (8%) |
History of seizure | 13 (5%) |
Thiotepa dose | |
600 mg/m2 | 129 (51%) |
720 mg/m2 | 76 (30%) |
900 mg/m2 | 46 (18%) |
Concomitant drugse | |
Alizapride | 94 (43%) |
Antibiotic | 49 (22%) |
Antidepressant | 7 (3%) |
Antipsychotic | 40 (18%) |
Aprepitant | 7 (3%) |
Benzodiazepine | 43 (20%) |
Histamine H2-receptor antagonist | 5 (2%) |
Proton Pump Inhibitor | 7 (3%) |
Analgesics | 92 (42%) |
Simple analgesics | 76 (35%) |
i.e. acetaminophen, nefopam | |
Weak opioids | 53 (24%) |
i.e. tramadol, codeine, dextropropoxyphen | |
Strong opioids | 9 (4%) |
i.e. morphine, pethidine |